Kainic acid, prototypic kainate receptor agonist (ab120100)
Key features and details
- Prototypic kainate receptor agonist
- CAS Number: 487-79-6
- Soluble in water to 25 mM
- Form / State: Solid
- Source: Digenea simplex
Overview
-
Product name
Kainic acid, prototypic kainate receptor agonist -
Description
Prototypic kainate receptor agonist -
Alternative names
- Kainate
-
Biological description
Prototypic agonist at the kainate class of ionotropic glutamate receptors. Potent excitant and neurotoxin, used to model epilepsy and neurodegenerative states. Also available in Kit(s): Ionotropic agonists (ab120323).
Also available in simple stock solutions (ab144490) - add 1 ml of water to get an exact, ready-to-use concentration. -
CAS Number
487-79-6 -
Chemical structure
Properties
-
Chemical name
(2S,3S,4S)-3-(Carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid -
Molecular weight
213.23 -
Molecular formula
C10H15NO4 -
PubChem identifier
10255 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in water to 25 mM -
Handling
This product is supplied in one (or more) pack size which is freeze dried. Therefore the contents may not be readily visible, as they can coat the bottom or walls of the vial. Please see our FAQs and information page for more details on handling.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O -
Source
Digenea simplex
-
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120100 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (58)
ab120100 has been referenced in 58 publications.
- Wu D et al. Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy. Sci Adv 8:eabm3381 (2022). PubMed: 35020438
- Chen KD et al. Augmented seizure susceptibility and hippocampal epileptogenesis in a translational mouse model of febrile status epilepticus. Epilepsia 62:647-658 (2021). PubMed: 33475157
- Wu K et al. Activity- and sleep-dependent regulation of tonic inhibition by Shisa7. Cell Rep 34:108899 (2021). PubMed: 33761345
- Nevoux J et al. An antibody to RGMa promotes regeneration of cochlear synapses after noise exposure. Sci Rep 11:2937 (2021). PubMed: 33536466
- Tang Y et al. Structure-based discovery of CZL80, a caspase-1 inhibitor with therapeutic potential for febrile seizures and later enhanced epileptogenic susceptibility. Br J Pharmacol 177:3519-3534 (2020). PubMed: 32346861
